ANCA-associated vasculitis, or AAV, is part of a group of rare autoimmune conditions that cause small blood vessel inflammation and damage, with approximately 70% of patients experiencing kidney involvement. Because of the significant mortality risk associated with each disease relapse, which leads to cumulative organ damage, timely diagnosis and early intervention are critical to improving patient outcomes. Through patient perspectives and case-based discussions, participants will explore early intervention strategies, the latest clinical practice guidelines (KDIGO and EULAR), and the role of newer therapeutic options for both short- and long-term management. Special emphasis will be placed on the importance of preserving kidney function through optimal induction and maintenance strategies to achieve optimal outcomes for patients with AAV.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.
